BioPorto A/S Sustainability Reports
BioPorto A/S is an in vitro diagnostics company focused on developing and commercializing biomarker-based tests. Its primary product line includes the NGAL Test used for the early risk assessment and diagnosis of acute kidney injury.
Sector: Professional & technical services
Country: Denmark
Exchange: Nasdaq Copenhagen
ISIN: DK0011048619
11 reports from 2015 to 2025